Q1 Earnings Forecast for JSPR Issued By HC Wainwright

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($1.48) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2025 earnings at ($1.63) EPS, Q3 2025 earnings at ($1.78) EPS, Q4 2025 earnings at ($1.93) EPS, FY2025 earnings at ($6.83) EPS, FY2026 earnings at ($8.17) EPS, FY2027 earnings at ($9.50) EPS and FY2028 earnings at ($10.61) EPS.

Several other analysts also recently issued reports on the company. BMO Capital Markets started coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target for the company. Royal Bank of Canada dropped their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, JMP Securities reissued a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research report on Monday, January 6th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $67.75.

Jasper Therapeutics Stock Up 0.9 %

Shares of JSPR stock opened at $7.05 on Monday. The company has a market capitalization of $105.76 million, a PE ratio of -1.49 and a beta of 2.18. Jasper Therapeutics has a 12-month low of $6.57 and a 12-month high of $31.01. The firm has a 50 day moving average price of $21.09 and a two-hundred day moving average price of $20.15.

Hedge Funds Weigh In On Jasper Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its stake in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after buying an additional 1,698 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at $59,000. MetLife Investment Management LLC grew its position in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after acquiring an additional 3,873 shares during the last quarter. Jane Street Group LLC acquired a new position in Jasper Therapeutics in the 3rd quarter worth about $251,000. Finally, Rhumbline Advisers bought a new position in Jasper Therapeutics in the second quarter valued at about $300,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.